Rosen Law Firm Urges REGENXBIO Shareholders with Losses to Contact Firm

Firm announces class action lawsuit on behalf of REGENXBIO investors over alleged misleading statements

Published on Feb. 17, 2026

Got story updates? Submit your updates here. ›

Rosen Law Firm, a global investor rights law firm, has announced a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026. The lawsuit alleges that REGENXBIO, a clinical-stage biotechnology company, misled investors regarding the efficacy and safety of its RGX-111 trial study.

Why it matters

The lawsuit claims that REGENXBIO provided investors with overwhelmingly positive statements about the future trial success of its RGX-111 product candidate, while at the same time disseminating false and misleading information or concealing material adverse facts about the actual efficacy and safety of the RGX-111 trial. This allegedly caused investors to suffer damages when the true details entered the market.

The details

According to the lawsuit, REGENXBIO made positive assertions about RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing Phase I/II study. However, the lawsuit claims the company was simultaneously disseminating false and misleading statements or concealing material adverse facts concerning the efficacy and safety of the RGX-111 trial.

  • The class period is from February 9, 2022 to January 27, 2026.
  • Shareholders have until April 14, 2026 to file motions to serve as lead plaintiff for the class.

The players

REGENXBIO, Inc.

A clinical-stage biotechnology company that is the subject of the class action lawsuit.

Rosen Law Firm

A global investor rights law firm that has announced the class action lawsuit against REGENXBIO.

Got photos? Submit your photos here. ›

What’s next

Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by April 14, 2026.

The takeaway

This case highlights the importance of transparency and accurate disclosure from biotechnology companies regarding the progress and results of their clinical trials, as investors rely on this information to make informed decisions. The lawsuit alleges REGENXBIO misled investors, which could have significant consequences for the company and its shareholders.